Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region

Accesswire March 26, 2024

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer

Business Wire March 21, 2024

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Business Wire March 19, 2024

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform

PR Newswire March 15, 2024

Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Business Wire March 15, 2024

Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

Business Wire March 13, 2024

Merck Completes Acquisition of Harpoon Therapeutics, Inc.

Business Wire March 11, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Business Wire March 6, 2024

Merck to Participate in the Barclays 26th Annual Global Healthcare Conference

Business Wire March 5, 2024

Merck to Participate in the Leerink Partners Global Biopharma Conference 2024

Business Wire March 4, 2024

Merck to Participate in the TD Cowen 44th Annual Health Care Conference

Business Wire February 27, 2024

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Business Wire February 23, 2024

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Business Wire February 20, 2024

Merck Is Inspiring Innovation Through Diversity and Inclusion

Accesswire February 13, 2024

Health Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumours express PD-L1 (CPS ≥ 1)

Canada NewsWire February 12, 2024

MERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE TO FURTHER ADVANCE ITS ARTIFICIAL INTELLIGENCE CAPABILITIES AND DRIVE INNOVATION IN HEALTHCARE

Canada NewsWire February 8, 2024

Merck Animal Health to Acquire Elanco's Aqua Business

Business Wire February 5, 2024

Elanco Announces Sale of Aqua Business for $1.3 Billion

PR Newswire February 5, 2024

Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results

Business Wire February 1, 2024

The Wall Street Journal Names Merck Among Top 10 Best-Managed Companies

Accesswire January 29, 2024